MedTrace Logo

Dovitinib in Neuroendocrine Tumors

NCT01635907 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-04-14

No results posted yet for this study

Summary

This study is being conducted to evaluate whether the investigational drug Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors. This study will also further evaluate the safety of this drug.

Conditions

  • Advanced Metastatic Paraganglioma
  • Advanced Metastatic Pheochromocytoma
  • Recurrent Paraganglioma
  • Recurrent Pheochromocytoma
  • Unresectable Paraganglioma
  • Unresectable Pheochromocytoma

Interventions

DRUG

Dovitinib

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Stephen Keefe, MD · Abramson Cancer Center at Penn Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2016-03-31
Completion
2016-04-11

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01635907 on ClinicalTrials.gov